# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Equal-Weight and raises the price target fr...
Stifel analyst Bradley Canino maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises the price target from $13 to $14.
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein d...
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein d...